NeoImmunis: The Next Evolution in Human Antibody Discovery
NeoImmunis is a private biotechnology company developing a new, fully human monoclonal antibody (mAb) platform based on transgenic rats. The rat is a widely used laboratory animal with a well characterized immune system, a complete genome sequence, and established transgenesis and hybridoma technologies. NeoImmunis emerges as a pioneering force in the field of antibody engineering, pushing the boundaries of how therapeutic antibodies are discovered, designed, and developed. With the growing global demand for targeted biologics in cancer, autoimmunity, and infectious diseases, NeoImmunis™ is setting new industry standards through its next-generation AI-integrated antibody platforms and multi-species transgenic models.
Antibodies are an important class of pharmaceutical products due to breakthroughs that have made them more human-like and eliminated unwanted side effects.
NeoImmunis is developing a transgenic rat for the generation of fully human monoclonal antibodies.Monoclonal antibodies (mAbs) have been the primary focus of medicine-development efforts since the early 1990s. Many pharmaceutical companies have entered the biologics market through acquiring antibody technologies or through licensing/fee for service arrangements.Up until now, the genetically engineered mice was the only animal-based human antibody platform available for developing new monoclonal antibodies. Pharmaceutical companies interested in licensing the transgenic mouse face:Limited target availability,Significant upfront license costs, andPotential milestones and royalty stacking.
NeoImmunis has invented a novel genetic engineering approach to generate fully human antibodies using transgenic rats.
The rat is a widely used laboratory animal with a well characterized immune system, a nearly complete genome sequence, and established transgenesis and hybridoma technologies.
We made two strategic innovations in NEO's genetic engineering - one which eliminated the suboptimal signaling by the B-cell receptor complex and the other which inactivated endogenous rat immunoglobulin genes.
Elimination of suboptimal signaling: NEO used hybrid constant region genes consisting of a human CH1-domain and rat CH2, CH3 and CH4 domains to overcome the suboptimal signaling of the B-cell receptor complex.
Inactivation of endogenous rat immunoglobulin genes: NEO collaborated with Sangamo Biosciences, Inc. to use a Zinc Finger Nuclease (ZFN) to delete critical regions of the rat immunoglobulin locus and create functional silencing of endogenous antibody expression
The development of NeoImmunis fully human monoclonal antibody platform has three major milestones. The generation of: (1) light chain transgenic animals, (2) heavy chain transgenic animals, and (3) knockout rats with inactivated immunoglobulin loci.Neo has created transgenic rats to serve as founders (F0) for the human light chain immunoglobulin (LC F0). NeoImmunis generated knock-out rats with mutated immunoglobulin heavy chain loci (KO F0). This milestone is featured in "Knockout Rats Produced via Embryo Microinjection of Designed Zinc Finger Nucleases". OMT is crossing these lines for homozygosity. 
NeoMouse®, a transgenic mouse model, complements the rat system by broadening the range of epitopes that can be targeted. It produces high-quality human antibodies with excellent specificity and functionality, making it a powerful tool in early-stage therapeutic antibody screening.
NeoFlic™ introduces a fixed light chain configuration in a rat model, uniquely positioned for the discovery of bispecific and bi-functional antibodies. This innovation supports the development of complex therapeutic formats with enhanced targeting and functional properties.
NeoRat® stands out as the first platform to utilize rats for the generation of fully human monoclonal antibodies. Engineered with a complete immune system, NeoRat offers an extensive antibody repertoire. This model enables rapid production of high-affinity antibodies with human idiotypes, ensuring strong expression, solubility, and structural stability—crucial characteristics for downstream clinical applications.
NeoAb™: A Triad of Antibody Discovery Innovation
🤖 AI-Driven Affinity Optimization and Epitope Prediction
2025 marks the integration of machine learning tools into antibody engineering pipelines. NeoImmunis™ uses proprietary deep learning algorithms trained on millions of antibody-antigen interactions to:
- Predict epitope accessibility with sub-angstrom accuracy
- Suggest CDR region edits to improve binding kinetics
- Model Fc-effector function modulation to fit disease-specific mechanisms
This AI-assisted design significantly reduces bench-to-clinic time for therapeutic antibody programs.
⚕️ Applications Across Therapeutic Frontiers In 2025, NeoImmunis™ technologies are already powering breakthroughs in:
- Personalized cancer immunotherapy
- Neuroinflammatory disease modulation
- Next-gen vaccine development
- Rapid pandemic-response biologics
Their cross-species validation system ensures translational relevance, reducing preclinical failure rates and increasing the probability of clinical success.
🌍 Global Licensing and Flexible Access
NeoImmunis™ offers modular licensing models to biopharmaceutical partners, CROs, and academic centers, supporting both large-scale antibody campaigns and targeted innovation projects. All platforms are patent-protected, and the company offers plug-and-play integration with existing antibody screening and expression systems.
Discover our blogs
Check out what's new in NeoImmunis !